[1]
|
M. Kumar, X. Zhao and X. W. Wang, “Molecular Carcinogenesis of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: One Step Closer to Personalized Medicine?” Cell & Bioscience, Vol. 1, No. 1, 2011, p. 5.
|
[2]
|
D. M. Parkin, F. Bray, J. Ferlay and P. Pisani, “Global Cancer Statistics,” CA: A Cancer Journal for Clinicians, Vol. 55, No. 1, 2005, pp. 74-108.
doi:10.3322/canjclin.55.2.74
|
[3]
|
A. K. Nowak, P. K Chow and M. Findlay, “Systemic Therapy for Advanced Hepatocellular Carcinoma: A Review,” European Journal of Cancer, Vol. 40, No. 10, 2004, pp. 1474-1484. doi:10.1016/j.ejca.2004.02.027
|
[4]
|
D. Wang and S. J. Lippard, “Cellular Processing of Platinum Anticancer Drugs,” Natural Reviews. Drug Discovery, Vol. 4, No. 4, 2005, pp. 307-320.
doi:10.1038/nrd1691
|
[5]
|
Y. X. Li, Z. B. Lin and H. R. Tan, “Wild Type p53 Increased Chemosensitivity of Drug-resistant Human Hepatocellular Carcinoma Bel7402/5-FU Cells,” Acta Pharmacologica Sinica, Vol. 25, No. 1, 2004, pp. 76-82.
|
[6]
|
M. Okamura, K. Hashimoto, J. Shimada and H. Sakagami, “Apoptosis-Inducing Activity of Cisplatin (CDDP) against Human Hepatoma and Oral Squamous Cell Carcinoma Cell Lines,” Anticancer Research, Vol. 24, No. 1, 2004, pp. 655-661.
|
[7]
|
H. Tanioka, et al., “Combination Chemotherapy with Continuous 5-Fluorouracil and Low-Dose Cisplatin Infusion for Advanced Hepatocellular Carcinoma,” Anticancer Research, Vol. 23, No. 1, 2003, pp. 1891-1897.
|
[8]
|
H. Nagai and Y. Smino, “Therapeutic Strategy for Advanced Hepatocellular Carcinoma by Using Combined Intra-Arterial Chemotherapy,” Recent Patents on Anticancer Drug Discovery, Vol. 3, No. 1, 2008, pp. 220-226.
doi:10.2174/157489208786242296
|
[9]
|
X. Yan, et al., “Biological Comparison of Ovarian Cancer Resistant Cell Lines to Cisplatin and Taxol by Two Different Administrations,” Oncology Reports, Vol. 17, No. 1, 2007, pp. 1163-1169.
|
[10]
|
D. Vandier, et al., “Transactivation of the Metallothionein Promoter in Cisplatin-Resistant Cancer Cells: A Specific Gene Therapy Strategy,” Journal of the Natinonal Cancer Institute, Vol. 92, No. 1, 2000, pp. 642-647.
doi:10.1093/jnci/92.8.642
|
[11]
|
A. K. Godwin, et al., “High Resistance to Cisplatin in Human Ovarian Cancer Cell Lines Is Associated with Marked Increase of Glutathione Synthesis,” Proceedings of the National Academy of Science of the United States of the America, Vol. 89, No. 7, 1992, pp. 3070-3074.
doi:10.1073/pnas.89.7.3070
|
[12]
|
S. Shibata, et al., “Measuring Cell Viability and Proliferation,” The Journal of Immunology, Vol. 177, No. 1, 2006, p. 3564.
|
[13]
|
L. Zhang, et al., “Fluorouracil Selectively Enriches Stem-like Leukemic Cells in a Leukemic Cell Line,” International Journal of Biological Sciences, Vol. 6, No. 5, 2010, pp. 419-427.
|
[14]
|
G. Chen, et al., “Prevalence of Multidrug Resistance Related to Activation of the mdr1 Gene in Human Sarcoma Mutants Derived by Single Step Doxorubicin Selection,” Cancer Research, Vol. 54, No. 1, 1994, pp. 4980-4987.
|
[15]
|
H. Takeshita, et al., “Experimental Models for the Study of Drug Resistance in Osteosarcoma: P-glycoprotein-Positive, Murine Osteosarcoma Cell Lines,” The Journal of Bone and Joint Surgery, Vol. 78, No. 1, 1996, pp. 366-375.
|
[16]
|
H. M. Coley, “Development of Drug-Resistant Models,” In: S. P. Langdon, Ed., Methods in Molecular Medicine, Vol. 88: Cancer Cell Culture: Methods and Protocols, Humana Press Inc, Totowa, 2004, pp. 267-274.
|
[17]
|
P. R. Twentyman, N. E. Fox, K. A. Wright and N. M. Bleehen, “Derivation and Preliminary Characterisation of Adriamycin-Resistant Lines of Human Lung Cancer Cells,” British Journal of Cancer, Vol. 53, No. 1, 1986, pp. 529-537. doi:10.1038/bjc.1986.83
|